1009640-20-3Relevant academic research and scientific papers
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4)inhibitors, compound profiling in cell-based target engagement assays
Le Bihan, Yann-Va?,Lanigan, Rachel M.,Atrash, Butrus,McLaughlin, Mark G.,Velupillai, Srikannathasan,Malcolm, Andrew G.,England, Katherine S.,Ruda, Gian Filippo,Mok, N. Yi,Tumber, Anthony,Tomlin, Kathy,Saville, Harry,Shehu, Erald,McAndrew, Craig,Carmichael, LeAnne,Bennett, James M.,Jeganathan, Fiona,Eve, Paul,Donovan, Adam,Hayes, Angela,Wood, Francesca,Raynaud, Florence I.,Fedorov, Oleg,Brennan, Paul E.,Burke, Rosemary,van Montfort, Rob L.M.,Rossanese, Olivia W.,Blagg, Julian,Bavetsias, Vassilios
, p. 316 - 337 (2019)
Residues in the histone substrate binding sites that differ between the KDM4 and KDM5 subfamilies were identified. Subsequently, a C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one series was designed to rationally exploit these residue differences between
HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
-
Page/Page column 60-61, (2008/06/13)
This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which is useful for the treatment of diseases or conditions mediated by LpxC.
